Plus Therapeutics Inc. (PSTV)
0.66
-0.06 (-8.97%)
At close: Mar 03, 2025, 3:59 PM
0.66
-0.23%
After-hours: Mar 03, 2025, 05:18 PM EST
No 1D chart data available
| Bid | 0.65 |
| Market Cap | 3.9M |
| Revenue (ttm) | 3.2M |
| Net Income (ttm) | -9.67M |
| EPS (ttm) | -2.4 |
| PE Ratio (ttm) | -0.28 |
| Forward PE | -0.57 |
| Analyst | Buy |
| Ask | 0.66 |
| Volume | 281,561 |
| Avg. Volume (20D) | 72,341 |
| Open | 0.70 |
| Previous Close | 0.72 |
| Day's Range | 0.63 - 0.72 |
| 52-Week Range | 0.63 - 2.67 |
| Beta | 0.70 |
About PSTV
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to d...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 11, 2001
Employees 20
Stock Exchange NASDAQ
Ticker Symbol PSTV
Website https://www.plustherapeutics.com
Analyst Forecast
According to 2 analyst ratings, the average rating for PSTV stock is "Buy." The 12-month stock price forecast is $13.5, which is an increase of 1943.29% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Plus Therapeutics Inc. is scheduled to release its earnings on Mar 14, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 days ago
+7.41%
Plus Therapeutics shares are trading higher after ...
Unlock content with
Pro Subscription
5 days ago
-29.63%
Plus Therapeutics shares are trading lower. The company announced it completed the ReSPECT-LM Phase 1 single-dose escalation trial
